ArticleFrontiers in molecular biosciences2023

A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations.

Ambritha Balasundaram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.